Become a Research Participant (COMMEND Study)


The COMMEND Study will assess the safety and effectiveness of an investigational product in men and women with motor neuron disease (MND) experiencing muscle cramps.  “Investigational” means that the treatment has not been approved for a particular clinical use and is still being evaluated.  Participants will be asked to take two study products during the course of the study.  One of these study products will be a placebo (this looks like the investigational product buy contains no active treatment). 

Approximately 150 participants in 30 study centers across the United States are expected to take part.  The study will last approximately 3 months, during which you will be asked to attend the study center three times to undergo medical tests and assessments.  You will also be contacted by telephone at various time points during the 3 months to assess your health and well-being.

You may be able to take part in the COMMEND Study if you:

  • Are 18 years of age or older
  • Have been diagnosed with MDN, including amyotrophic lateral sclerosis, primary lateral sclerosis, or progressive muscular atrophy
  • Have experienced muscle cramps over the past 4 weeks

There are other criteria that you will need to meet to participate in the study; the study team will assess and talk through them with you.  They study team will also discuss the potential benefits and risks of being involved in the study, and explain what participating would mean for you.

Throughout the study, your health will be monitored through regular medical tests and procedures.  Participation can be stopped if you or your study doctor have concerns or if you change your mind about being in the study.  You are allowed to leave the study at any time.  There will be no charge for any study-related treatment or care. 

If you would like to learn more about the COMMEND Study, visit or contact us at (412) 647-1706, (412) 864-2873, or email us at  Contacting us does not mean that you are required to take part in the study.

Thank you for your consideration.

The COMMEND Study Team